Abstract:Cancer remains a primary threat to human lives. Recently, amplification of tumor-associated reactive oxygen species (ROS) has been used as a boosting strategy to improve tumor therapy. Here, we report on a bone-targeting prodrug mesoporous silica-based nanoreactor for combined photodynamic therapy (PDT) and enhanced chemotherapy for osteosarcoma. Because of surface modification of a bone-targeting biphosphate moiety and the enhanced permeability and retention effect, the formed nanoreactor shows efficient accumulation in osteosarcoma and exhibits long-term retention in the tumor microenvironment. Upon laser irradiation, the loaded photosensitizer chlorin e6 (Ce6) produces in situ ROS, which not only works for PDT but also functions as a trigger for controlled release of doxorubicin (DOX) and doxycycline (DOXY) from the prodrugs based on a thioketal (<i>TK</i>) linkage. The released DOXY further promotes ROS production, thus perpetuating subsequent DOX/DOXY release and ROS burst. The ROS amplification induces long-term high oxidative stress, which increases the sensitivity of the osteosarcoma to chemotherapy, therefore resulting in enhanced tumor cell inhibition and apoptosis. The as-developed nanoreactor with combined PDT and enhanced chemotherapy based on ROS amplification shows significant promise as a potential platform for cancer treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c08992?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c08992</a>.1H NMR spectra of TK, DOX-TK, and DOX-TK-DOXY; inverted fluorescence microscopy images and cell apoptosis with TUNEL staining and cell cycle analyses of OS-732 cells; loading contents of Ce6 for /MSN/DOX-TK-DOXY; particle size, UV-vis absorption spectra, and DOX and DOXY release profiles of /MSN/DOX-TK-DOXY; phototriggered intracellular DOX and DOXY release; intracellular ROS production in OS-732 cells; cell apoptosis with TUNEL staining of OS-732 cells treated with /MSN/DOX-TK-DOXY; MTP measurements for /MSN/DOX-TK-DOX; OS-732 cell metabolism after different treatments; body weights of mice bearing OS-732 tumors; ROS analysis in tumor tissues after treatment with /MSN/DOX-TK-DOXY; inner ring tumor microvessel tortuosity and density; HE staining of main organs after treatment; CD31 expression and RT-PCR analyses of tumor vessels; and quantification of DOX and DOXY contents in major organs (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c08992/suppl_file/am0c08992_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

ROS-responsive glycol chitosan-linked prodrug nanoparticle as a nanoplatform for tumor chemo-photodynamic therapy

Polymeric Nanoparticles with ROS‐Responsive Prodrug and Platinum Nanozyme for Enhanced Chemophotodynamic Therapy of Colon Cancer

ROS-responsive cyclodextrin nanoplatform for combined photodynamic therapy and chemotherapy of cancer

ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer

Gold Nanoparticle-Decorated G-C3n4 Nanosheets for Controlled Generation of Reactive Oxygen Species Upon 670 Nm Laser Illumination.

Dual-Responsive and ROS-Augmented Nanoplatform for Chemo/Photodynamic/Chemodynamic Combination Therapy of Triple Negative Breast Cancer.

ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic therapy

ROS‐Responsive Camptothecin Prodrug Nanoparticles for On‐Demand Drug Release and Combination of Chemotherapy and Photodynamic Therapy

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

Chitosan derivatives functionalized dual ROS-responsive nanocarriers to enhance synergistic oxidation-chemotherapy

Reactive Oxygen Species Activatable Heterodimeric Prodrug as Tumor-Selective Nanotheranostics

A Triple‐Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H2O2 Self‐Generation for Imaging‐Guided Tumor Chemo‐Ferroptosis‐Immunotherapy (Adv. Healthcare Mater. 16/2024)

Formulation of DOX-dimer with bi-functionalized chitooligosaccharide for tumor-specific self-boosted drug release and synergistic chemo/chemodynamic therapy

Tumor-targeting polymer nanohybrids with amplified ROS generation for combined photodynamic and chemodynamic therapy

A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors

An Enzyme-responsive Porphyrin Metal-organic Framework Nanosystem for Targeted and Enhanced Synergistic Cancer Photo-chemo Therapy

ROS-Responsive Polymeric Nanocarriers with Photoinduced Exposure of Cell-Penetrating Moieties for Specific Intracellular Drug Delivery

Bone-Targeting Prodrug Mesoporous Silica-Based Nanoreactor with Reactive Oxygen Species Burst for Enhanced Chemotherapy

Bioresponsive Prodrug Nanogel-Based Polycondensate Strategy Deepens Tumor Penetration and Potentiates Oxidative Stress

Photodynamic‐Chemodynamic Cascade Reactions for Efficient Drug Delivery and Enhanced Combination Therapy

Development of Photo-Activated ROS-Responsive Nanoplatform as a Dual-Functional Drug Carrier in Combinational Chemo-Photodynamic Therapy